[go: up one dir, main page]

PE20030665A1 - ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a - Google Patents

ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a

Info

Publication number
PE20030665A1
PE20030665A1 PE2002001143A PE2002001143A PE20030665A1 PE 20030665 A1 PE20030665 A1 PE 20030665A1 PE 2002001143 A PE2002001143 A PE 2002001143A PE 2002001143 A PE2002001143 A PE 2002001143A PE 20030665 A1 PE20030665 A1 PE 20030665A1
Authority
PE
Peru
Prior art keywords
aryl
inhibitors
adenosine
azepanil
piperidinyl
Prior art date
Application number
PE2002001143A
Other languages
English (en)
Inventor
Craig D Boyle
Samuel Chackalamannil
Yan Xia
Unmesh G Shah
William J Greenlee
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20030665A1 publication Critical patent/PE20030665A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTO CONDENSADO TRIAZO PIRIMIDIN PIRAZOL DE FORMULA I DONDE R ES R1-FURANILO, R1-TIENILO, R1-PIRIDILO, R1-OXAZOLILO, R1-PIRROLILO, R2-ARILO; X ES (CH2)n, Y ES PIPERIDINILO, PIRROLIDINILO, AZEPANILO, CON UNA PORCION ARILO O HETEROARILO FUSIONADA A DOS ATOMOS DE CARBONO ADYACENTE EN Y, X ESTA UNIDO AL ATOMO DE N DEL PIPERIDINILO, PIRROLIDINILO, AZEPANILO; Q ES H, CICLOALQUILO, CICLOHETEROALQUILO, AMINO, ARILO, ARALQUILO, HETEROARILO, ENTRE OTROS; n ES 1-4; R1 ES H, ALQUILO, CF3, HALOGENO, NO2; R2 ES H, ALQUILO, CF3, HALOGENO, NO2, ALCOXI, ACILOXI, ALQUILAMINO, ACILAMINO, ALQUILSULFONLO, HIDROXILO. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS AGONISTAS DOPAMINERGICOS, INHIBIDORES DE MAO-B, INHIBIDORES DE DOPA DESCARBOXILASA, INHIBIDORES DE COMT. LOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDAD DEL SISTEMA NERVIOSO CENTRAL, APOPLEJIA, ENFERMEDAD COGNITIVA, NEURODEGENERATIVA, PARKINSON, DEMENCIA SENIL
PE2002001143A 2001-11-30 2002-11-27 ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a PE20030665A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33434201P 2001-11-30 2001-11-30

Publications (1)

Publication Number Publication Date
PE20030665A1 true PE20030665A1 (es) 2003-08-08

Family

ID=23306779

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001143A PE20030665A1 (es) 2001-11-30 2002-11-27 ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a

Country Status (18)

Country Link
US (1) US6916811B2 (es)
EP (1) EP1448565B1 (es)
JP (2) JP4284182B2 (es)
KR (1) KR20050044593A (es)
CN (1) CN1692116A (es)
AR (1) AR037680A1 (es)
AT (1) ATE453647T1 (es)
AU (1) AU2002346503A1 (es)
CA (1) CA2468649C (es)
DE (1) DE60234951D1 (es)
ES (1) ES2336435T3 (es)
HU (1) HUP0402018A3 (es)
IL (1) IL161716A0 (es)
MX (1) MXPA04005209A (es)
PE (1) PE20030665A1 (es)
TW (1) TW200306837A (es)
WO (1) WO2003048165A1 (es)
ZA (1) ZA200404161B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6808901A (en) * 2000-05-26 2001-12-11 Schering Corp Adenosine a2a receptor antagonists
US6964288B2 (en) * 2001-07-06 2005-11-15 Ksaria Corporation Apparatus and method for automated preparation of an optical fiber
MXPA04003474A (es) 2001-10-15 2004-07-30 Schering Corp Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pirimidinas como antagonistas del receptor de adenosina a2a.
BR0304963A (pt) * 2002-05-30 2004-09-28 King Pharmaceuticals Res & Dev Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças
ES2354875T3 (es) 2002-12-19 2011-03-18 Schering Corporation Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal.
CA2541989C (en) * 2003-10-24 2013-10-01 Exelixis, Inc. P70s6 kinase modulators and method of use
HRP20070063T3 (hr) * 2003-10-28 2007-04-30 Schering Corporation POSTUPAK DOBIVANJA SUPSTITUIRANIH 5-AMINOPIRAZOLO[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA
US20060009504A1 (en) * 2003-12-19 2006-01-12 Schering Corporation Pharmaceutical compositions
JPWO2006132275A1 (ja) * 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および/または治療剤
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
US8288397B2 (en) 2007-12-17 2012-10-16 Janssen Pharmaceutica Nv Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1
US12246013B2 (en) 2008-08-01 2025-03-11 Eye Therapies Llc Vasoconstriction compositions and methods of use
PT2320911E (pt) 2008-08-01 2014-11-11 Eye Therapies Llc Composições de vasoconstrição e métodos de utilização
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
AU2009335019A1 (en) 2008-12-30 2011-08-18 Arqule, Inc. Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
WO2010114894A1 (en) 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CA2782872A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
MA55142A (fr) 2018-11-20 2022-02-23 Merck Sharp & Dohme Amino-triazolopyrimidine et amino-triazolopyrazine substitués antagoniste du récepteur de l'adénosine, compositions pharmaceutiques et leur utilisation
CA3120862C (en) 2018-11-30 2024-05-07 Merck Sharp & Dohme Corp. 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020112706A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
EP3999513A4 (en) * 2019-07-17 2022-12-21 Teon Therapeutics, Inc. ADENOSIN A2A RECEPTOR ANTAGONISTS AND USES THEREOF
CN112479956A (zh) 2019-07-30 2021-03-12 杭州阿诺生物医药科技有限公司 一种用于制备腺苷受体抑制剂中间体的方法
CN112625050B (zh) 2019-07-30 2021-10-01 杭州阿诺生物医药科技有限公司 一种a2a和/或a2b受体抑制剂的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) * 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) * 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
AU6808901A (en) * 2000-05-26 2001-12-11 Schering Corp Adenosine a2a receptor antagonists
BR0304963A (pt) * 2002-05-30 2004-09-28 King Pharmaceuticals Res & Dev Compostos, composição farmacêutica, e, métodos para modular a atividade de adenosina em um mamìfero, e para tratar um mamìfero sofrendo de ou suscetìvel às doenças
MY139344A (en) * 2003-04-23 2009-09-30 Schering Corp 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
ATE453647T1 (de) 2010-01-15
HK1063780A1 (en) 2005-01-14
HUP0402018A2 (hu) 2005-02-28
JP2005511699A (ja) 2005-04-28
CA2468649A1 (en) 2003-06-12
HUP0402018A3 (en) 2008-06-30
CA2468649C (en) 2009-03-10
ES2336435T3 (es) 2010-04-13
DE60234951D1 (de) 2010-02-11
EP1448565A1 (en) 2004-08-25
AU2002346503A1 (en) 2003-06-17
AR037680A1 (es) 2004-12-01
JP2008260776A (ja) 2008-10-30
MXPA04005209A (es) 2004-08-19
WO2003048165A1 (en) 2003-06-12
US20030212059A1 (en) 2003-11-13
JP4284182B2 (ja) 2009-06-24
EP1448565B1 (en) 2009-12-30
KR20050044593A (ko) 2005-05-12
CN1692116A (zh) 2005-11-02
ZA200404161B (en) 2005-11-30
IL161716A0 (en) 2004-09-27
TW200306837A (en) 2003-12-01
US6916811B2 (en) 2005-07-12

Similar Documents

Publication Publication Date Title
PE20030665A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20030477A1 (es) ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a
PE20060873A1 (es) Compuestos de quinolina heteroaromaticos
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
CY1114022T1 (el) Φαρμακα με δραση υποδοχεα ημ74α
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
ECSP056072A (es) Pirimidinonas sustituidas
PE20040450A1 (es) Heteroariloxi-aril-espiro-pirimidina-2,4,6-triona n-sustituida como inhibidores de metaloproteinasa
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
SG166019A1 (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
DE60235396D1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
UY28150A1 (es) Agentes terapeuticos
PE20070832A1 (es) Derivados de piridazinona como inhibidores de la tirosina quinasa
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
AR052312A1 (es) 2- anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y medicamentos preparados en base al compuesto
ATE342896T1 (de) Fluoreszierende proben zur quantitativen bestimmung von zink
PA8575001A1 (es) Fluorobenzamidas como inhibidores de maob
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
PE20061378A1 (es) INHIBIDORES DE LA ACTIVIDAD DE Akt

Legal Events

Date Code Title Description
FC Refusal